XNAS · Healthcare · Biotechnology
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-30 | Q1 2026 | -0.23 | -0.15 | +34.78% | $0 | ✅ Beat | -16.77% | -20.08% | -18.27% |
| 2026-02-23 | Q4 2025 | -0.10 | -0.14 | -40.00% | $0 | ❌ Miss | +0.25% | +0.62% | +11.50% |
| 2025-10-20 |
| Q3 2025 |
| -0.08 |
| -0.13 |
| -62.50% |
| $0 |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-11 | Q2 2025 | -0.08 | -0.12 | -50.00% | $0 | ❌ Miss | — | — | — |
| 2025-02-24 | Q4 2024 | -0.08 | -0.07 | +12.50% | $0 | ✅ Beat | -3.87% | +1.54% | +5.57% |
| 2024-08-06 | Q2 2024 | -0.06 | -0.05 | +16.67% | $0 | ✅ Beat | -1.47% | +17.92% | +31.03% |
| 2024-05-01 | Q1 2024 | — | -0.06 | — | $0 | — | -13.62% | +5.53% | +84.79% |
| 2024-02-20 | Q4 2023 | — | -0.05 | — | $0 | — | — | — | — |
Showing last 8 quarters.